Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don M Benson

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Blood Cancer Journal|July 27, 2022
Racial differences as predictors of outcomes in young patients with multiple myelomaAlicia Bao, Qiuhong Zhao, Elizabeth Merritt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 20, 2014
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II studyThomas Bechtel, Ali McBride, Brooke Crawford, et al.
Frontiers in Oncology|March 4, 2021
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma PatientsFrancesca Cottini, Ying Huang, Nita Williams, et al.
Cancer Immunology, Immunotherapy : CII|January 15, 2008
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assaySri Vidya Kondadasula, Kimberly A Varker, Gregory B Lesinski, et al.
Leukemia|April 22, 2018
Ninety-minute daratumumab infusion is safe in multiple myelomaHallie Barr, Jessica Dempsey, Allyson Waller, et al.
Blood|May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myelomaThomas Martin, Rachid Baz, Don M Benson, et al.
Blood|December 9, 2008
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cellsDon M Benson, Jianhua Yu, Brian Becknell, et al.
Leukemia & Lymphoma|October 3, 2018
Most multiple myeloma patients have low testosteroneSonya John, Nidhi Sharma, Douglas W Sborov, et al.
Cancer Discovery|July 26, 2019
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic EffectorWenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Leukemia & Lymphoma|December 30, 2009
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myelomaDon M Benson, Kathryn Panzner, Mehdi Hamadani, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Blood Cancer Journal|July 27, 2022
Racial differences as predictors of outcomes in young patients with multiple myelomaAlicia Bao, Qiuhong Zhao, Elizabeth Merritt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 20, 2014
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II studyThomas Bechtel, Ali McBride, Brooke Crawford, et al.
Frontiers in Oncology|March 4, 2021
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma PatientsFrancesca Cottini, Ying Huang, Nita Williams, et al.
Cancer Immunology, Immunotherapy : CII|January 15, 2008
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assaySri Vidya Kondadasula, Kimberly A Varker, Gregory B Lesinski, et al.
Leukemia|April 22, 2018
Ninety-minute daratumumab infusion is safe in multiple myelomaHallie Barr, Jessica Dempsey, Allyson Waller, et al.
Blood|May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myelomaThomas Martin, Rachid Baz, Don M Benson, et al.
Blood|December 9, 2008
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cellsDon M Benson, Jianhua Yu, Brian Becknell, et al.
Leukemia & Lymphoma|October 3, 2018
Most multiple myeloma patients have low testosteroneSonya John, Nidhi Sharma, Douglas W Sborov, et al.
Cancer Discovery|July 26, 2019
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic EffectorWenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Leukemia & Lymphoma|December 30, 2009
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myelomaDon M Benson, Kathryn Panzner, Mehdi Hamadani, et al.
Pageof 11